Uncertainty in the Workplace in Europe - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Uncertainty in the Workplace in Europe
Industry mergers, acquisitions and downsizing contribute to uncertainty in job security.


Pharmaceutical Technology
Volume 37, Issue 12, pp. 28-31
2013 Pharmaceutical Technology Europe Employment Survey
Photo Credit: kizilkayaphotos/Maria Toutoudaki/Getty Images; Dan Ward

This article was originally published in the December 2013 issue of Pharmaceutical Technology Europe magazine.

Amid the environment of a gradual economic recovery and continued consolidation of bio/pharmaceutical companies, scientists, technicians and professionals involved in drug development expressed a mix of muted optimism and stagnant employment options in an annual employment survey conducted by Pharmaceutical Technology Europe and its sister publication BioPharm International (1). The respondents represent a cross section of small- and large-molecule drug development from facilities in Europe.

 

In the past two years, have you been through a merger, acquisition, downsizing or restructuring?

 

YES

NO

2012

36.1%

63.9%

2013

50.4%

49.6%

 

 

In 2013, about half of the European respondents said they were involved in a merger, acquisition, downsizing or restructuring. This response represents a significant jump from 2012, when 36.1% of survey participants experienced similar company changes. In a survey of bio/pharmaceutical professionals in North America, respondents reported similar experiences with company restructuring. Respondents from other parts of the world, however, felt more secure in their jobs than their counterparts in Europe.

Since 2011, the number of respondents who expressed confidence in the security of their jobs has declined from 14.3% to 11.5%. The percentage of respondents who said they were less secure in their position versus the previous year dropped from 46.2% in 2011 to about 40% in 2013. More people reported no change.

How secure do you feel in your job compared with the last two years?
How secure do you feel in your job compared with the last two years?
Job security legend

 

Does your salary reflect a change over last year’s salary?

Increase

39.3%

Decrease

11.1%

No change

49.6%

 

Nearly half of those surveyed (49.6%) reported no change in salary in 2013; almost 40% reported increases. While 34.6% said they were paid fairly, 41.3% said their compensation was at the lower range of market value and nearly one-quarter said they were paid below market value.

 

Rate your satisfaction with your current salary
(for your level of expertise and responsibility).

I am paid excessively

0.8%

I am paid fairly

34.6%

I am paid within market value, but at the low end of the range

41.3%

I am paid below market value

23.3%

Nearly two-thirds of the respondents reported an increase in workload in 2013 versus 2012. However, this number is still below the 76.1% who reported an added workload in 2011.

 

Within the past two years, has your workload increased, decreased or stayed the same?
Within the past two years, has your workload increased, decreased or stayed the same?
Workload legent

However, respondents cited other factors as important to job satisfaction including intellectual stimulation, challenging projects or good work/life balance as “the main reason I come to work.”

This is the main reason I come to work.
This is the main reason I come to work.

Intellectual challenge and work/life balance were the two most important reasons respondents would change jobs, followed by professional advancement and salary. More than half were confident that they could find a job comparable to the one they currently hold; however, almost 35% said it may take a while to secure a comparable position. One-quarter said they expected a job search to be difficult.

I would change jobs for this alone.
I would change jobs for this alone.

While they held some reservations about prospects for their own positions, respondents were more optimistic about business prospects for their organisations and the overall bio/pharmaceutical industry. More than 54% predict business prospects for their company will improve in 2014, a jump of more than 16 percentage points over last year. The percent of respondents who thought business would decline dropped from 27% in 2012 to 11.7% in 2013.

What is your prediction for your company’s business prospects in the coming year?
What is your prediction for your company’s business prospects in the coming year?

 

In your view, what is the general outlook for the bio/pharmaceutical industry in the short- and long-term?
In your view, what is the general outlook for the
bio/pharmaceutical industry in the short- and long-term?

However, when considering the outlook for the overall bio/pharmaceutical market in the short- and long-term, 37.5% of the respondents predicted that business will improve, compared to 45% who anticipated improvements in 2012. Interestingly, more survey participants expect business to improve overseas, but not domestically (21.8%)

References
1. 2013 Pharmaceutical Technology/BioPharm International Employment Survey.

Note: Due to rounding, some percentages may not add up to 100%. Some questions allowed multiple answers.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here